Compare UTG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTG | NAMS |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | 2003 | 2022 |
| Metric | UTG | NAMS |
|---|---|---|
| Price | $38.33 | $25.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.75 |
| AVG Volume (30 Days) | 236.0K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,000.00 |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.81 | $23.05 |
| 52 Week High | $43.90 | $42.21 |
| Indicator | UTG | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 38.58 |
| Support Level | $37.36 | N/A |
| Resistance Level | $38.49 | $28.87 |
| Average True Range (ATR) | 0.65 | 0.98 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 19.08 | 25.00 |
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.